January 25th 2024
The expanded indication makes dupilumab the only approved treatment for eosinophilic esophagitis (EoE) in this age group.
Turning Food Allergy Triggers Into Therapy: A Managed Care Lens on Immunotherapy and Targeted Biologics
1.5 Credits / Immunology
View More
Targeted Therapies for the Management of Eosinophilic Esophagitis Across the Life Cycle: The Role of the Pharmacist in Patient Identification and Optimization, featuring a Pat...
1.5 Credits / Immunology
View More
Managed Care Perspectives on the Burden of Food Allergies and Advances in Treatment
1.5 Credits / Allergy, Immunology
View More
Treatment Improves Outcomes in Patients With CRSwNP, Features of Obstructive Lung Disease
May 19th 2023In the phase 3 SINUS-24 and SINUS-52 trials, dupilumab improved clinical outcomes and and health-related quality of life among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and clinical features of obstructive lung disease.
Read More
Patients With EoE Benefit From Systemic Treatment Regardless of Esophageal Dilation History
May 10th 2023Treatment with dupilumab demonstrated improvements in histological markers, symptoms, and endoscopic markers of eosinophilic esophagitis (EoE) regardless of previous history of esophageal dilation.
Read More
Study Links Early Pet Exposure, Reduced Food Allergy Incidence in Japanese Children
April 7th 2023Exposure to pets during fetal development or early infancy was associated with reduced instances of food allergies in young children, with different pet exposures potentially reducing the incidence risk of certain allergen types.
Read More
Prurigo Nodularis Improves Following Treatment With Dupilumab
March 30th 2023Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the monoclonal antibody for the chronic inflammatory skin condition.
Read More
Patient Outcomes Improve on Several Fronts Following Treatment for Prurigo Nodularis
March 20th 2023Subanalyses of data from the LIBERTY PN-PRIME and LIBERTY PN-PRIME2 studies illustrate how dupilumab for prurigo nodularis can better patient outcomes, including quality of life and symptom burden.
Read More
Trio of Scales Deemed Valid, Reliable for Use in Prurigo Nodularis
March 16th 2023The Skin Pain Numeric Rating Scale, Worst-Itch Numeric Rating Scale, and Dermatology Life Quality Index were evaluated for their content validity, fit-for-purpose, and psychometric and measurement properties among patients with the chronic skin disease being treated with dupilumab.
Read More
FDA Accepts Application for Dupilumab to Treat Chronic Spontaneous Urticaria
March 7th 2023The supplemental Biologics License Application was filed for the new indication for dupilumab, which is already approved to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
Read More
Periostin Bests Eosinophil Count for Biomarker Predictability in ECRS
February 2nd 2023Known to be a contributing factor to polyp development at high levels, periostin’s potential as a biomarker for eosinophilic chronic rhinosinusitis (ECRS) severity was investigated in a new study in which outcomes were compared between patients who had ECRS and those with non-ECRS.
Read More
Early Diagnosis Vital to Prevent Impairment From Pediatric EGIDs
January 20th 2023Although it is well studied in adult patients, there is a lack of research on eosinophilic gastrointestinal disorders (EGIDs) among pediatric patients; a recent study aimed to add to the clinical knowledge of EGIDs in younger patients.
Read More
Adherence to Postop Treatment May Indicate Early Recurrence of CRSwNP
January 17th 2023The utility of and adherence to follow-up exams for potential recurrence of chronic rhinosinusitis with nasal polyps (CRSwNP) was investigated among 60 patients who had undergone functional endoscopic sinus surgery.
Read More
Interleukin-13, Periostin Show Potential as Biomarkers in Prurigo Nodularis
January 7th 2023Levels of certain biomarkers of inflammation in prurigo nodularis were evaluated between patients with and without the chronic inflammatory skin disorder, with the goal of showing potential for precision medicine in prurigo nodularis.
Read More
Risk of EoE Elevated Following Care for Previous Infection
January 6th 2023With previous research showing that having a history of infection can lead to loss of autoimmunity, Swedish researchers set out to investigate a potential link between prior infection and development of eosinophilic esophagitis (EoE).
Read More